Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more
Medigen Vaccine Biologics (6547) - Total Assets
Latest total assets as of September 2025: NT$4.07 Billion TWD
Based on the latest financial reports, Medigen Vaccine Biologics (6547) holds total assets worth NT$4.07 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Medigen Vaccine Biologics - Total Assets Trend (2012–2024)
This chart illustrates how Medigen Vaccine Biologics’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Medigen Vaccine Biologics - Asset Composition Analysis
Current Asset Composition (December 2024)
Medigen Vaccine Biologics's total assets of NT$4.07 Billion consist of 58.6% current assets and 41.4% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 16.4% |
| Accounts Receivable | NT$118.03 Million | 2.7% |
| Inventory | NT$452.06 Million | 10.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Medigen Vaccine Biologics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medigen Vaccine Biologics's current assets represent 58.6% of total assets in 2024, an increase from 30.0% in 2012.
- Cash Position: Cash and equivalents constituted 16.4% of total assets in 2024, down from 26.5% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 65.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 10.4% of total assets.
Medigen Vaccine Biologics Competitors by Total Assets
Key competitors of Medigen Vaccine Biologics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Medigen Vaccine Biologics - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Medigen Vaccine Biologics generates 0.14x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Medigen Vaccine Biologics is currently not profitable relative to its asset base.
Medigen Vaccine Biologics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.12 | 12.69 | 12.48 |
| Quick Ratio | 11.37 | 10.52 | 12.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$2.28 Billion | NT$ 2.34 Billion | NT$ 1.85 Billion |
Medigen Vaccine Biologics - Advanced Valuation Insights
This section examines the relationship between Medigen Vaccine Biologics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.40 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -28.4% |
| Total Assets | NT$4.36 Billion |
| Market Capitalization | $283.60 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medigen Vaccine Biologics's assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Medigen Vaccine Biologics's assets decreased by 28.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Medigen Vaccine Biologics (2012–2024)
The table below shows the annual total assets of Medigen Vaccine Biologics from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$4.36 Billion | -28.37% |
| 2023-12-31 | NT$6.09 Billion | -17.08% |
| 2022-12-31 | NT$7.35 Billion | +38.66% |
| 2021-12-31 | NT$5.30 Billion | +51.80% |
| 2020-12-31 | NT$3.49 Billion | +53.30% |
| 2019-12-31 | NT$2.28 Billion | +4.30% |
| 2018-12-31 | NT$2.18 Billion | +2.18% |
| 2017-12-31 | NT$2.14 Billion | +17.56% |
| 2016-12-31 | NT$1.82 Billion | +9.91% |
| 2015-12-31 | NT$1.65 Billion | +36.13% |
| 2014-12-31 | NT$1.21 Billion | +154.43% |
| 2013-12-31 | NT$477.40 Million | +217.95% |
| 2012-12-31 | NT$150.15 Million | -- |